Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Cora N. Sternberg, Giuseppe Procopio et al.|Clinical Cancer Research|2019Cited by 240
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Sérgio Rizzo et al.|The Lancet Oncology|2018Cited by 88
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Mauro Magnani, Francesco Graziano et al.|British Journal of Cancer|2017Cited by 68
EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencingLucio Lettig, Daniela Furlan, Nora Sahnane et al.|Translational Lung Cancer Research|2019Cited by 50
Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF MutationNunzio Digiacomo, Daniela Furlan, Elena Bolzacchini et al.|Clinical Colorectal Cancer|2018Cited by 21